Perfluoropentanesulfonic acid

B₆C₃F₁ mice (female, 7-8 weeks of age)^[2]

56 mg/kg; 113 mg/kg; 225 mg/kg

topical; daily; 28 days

Increased serum PFPeS concentrations to 41 μg/mL (56 mg/kg), 79.8 μg/mL (113 mg/kg), 119.2 μg/mL (225 mg/kg) relative to vehicle control.
Increased urine PFPeS concentrations to 220 μg/mL (56 mg/kg), 430 μg/mL (113 mg/kg), 470 μg/mL (225 mg/kg) relative to vehicle control.
Increased relative liver weights by 32% (56 mg/kg), 63% (113 mg/kg), and a greater magnitude (225 mg/kg) compared to vehicle controls.
Increased absolute liver weights significantly at all three doses compared to vehicle controls.
Decreased relative spleen weight by 18% at the 225 mg/kg dose compared to vehicle controls.
Increased serum glucose by 28% (56 mg/kg), 24% (113 mg/kg), and 25% (225 mg/kg) compared to vehicle controls.
Increased serum alkaline phosphatase (ALKP) by 47% at the 225 mg/kg dose compared to vehicle controls.
Induced minimal hepatocellular hypertrophy in 3/5 mice, mild hypertrophy in 1/5 mice (56 mg/kg); mild hypertrophy in all 5 mice (113 mg/kg); moderate hypertrophy in all 5 mice (225 mg/kg).
Induced minimal hepatocyte necrosis in 3/5 mice (113 mg/kg) and 2/5 mice (225 mg/kg).
Induced minimal epidermal hyperplasia in all 5 mice, minimal mixed cell inflammation in the dermis in 3/5 mice (225 mg/kg).